HUP0103773A3 - Reversal of viral-induced systemic schock and respiratory distress by blockade of the lymphotoxin beta pathway - Google Patents

Reversal of viral-induced systemic schock and respiratory distress by blockade of the lymphotoxin beta pathway

Info

Publication number
HUP0103773A3
HUP0103773A3 HU0103773A HUP0103773A HUP0103773A3 HU P0103773 A3 HUP0103773 A3 HU P0103773A3 HU 0103773 A HU0103773 A HU 0103773A HU P0103773 A HUP0103773 A HU P0103773A HU P0103773 A3 HUP0103773 A3 HU P0103773A3
Authority
HU
Hungary
Prior art keywords
schock
blockade
reversal
viral
respiratory distress
Prior art date
Application number
HU0103773A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Biogen Idec Ma Inc Cambridge
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Ma Inc Cambridge filed Critical Biogen Idec Ma Inc Cambridge
Publication of HUP0103773A2 publication Critical patent/HUP0103773A2/hu
Publication of HUP0103773A3 publication Critical patent/HUP0103773A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C07K16/242—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HU0103773A 1998-10-09 1999-10-08 Reversal of viral-induced systemic schock and respiratory distress by blockade of the lymphotoxin beta pathway HUP0103773A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10366298P 1998-10-09 1998-10-09
PCT/US1999/023477 WO2000021558A1 (en) 1998-10-09 1999-10-08 Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway

Publications (2)

Publication Number Publication Date
HUP0103773A2 HUP0103773A2 (hu) 2002-01-28
HUP0103773A3 true HUP0103773A3 (en) 2003-10-28

Family

ID=22296372

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0103773A HUP0103773A3 (en) 1998-10-09 1999-10-08 Reversal of viral-induced systemic schock and respiratory distress by blockade of the lymphotoxin beta pathway

Country Status (27)

Country Link
US (3) US20020001585A1 (enExample)
EP (1) EP1119370B1 (enExample)
JP (2) JP4713738B2 (enExample)
KR (1) KR100888832B1 (enExample)
CN (1) CN1200733C (enExample)
AT (1) ATE329618T1 (enExample)
AU (1) AU777492C (enExample)
BR (1) BR9915025A (enExample)
CA (1) CA2344049C (enExample)
CY (1) CY1105059T1 (enExample)
CZ (1) CZ20011272A3 (enExample)
DE (1) DE69931944T2 (enExample)
DK (1) DK1119370T3 (enExample)
EA (1) EA006703B1 (enExample)
EE (1) EE04661B1 (enExample)
ES (1) ES2267294T3 (enExample)
HU (1) HUP0103773A3 (enExample)
IL (2) IL142284A0 (enExample)
IS (1) IS2514B (enExample)
NO (1) NO326905B1 (enExample)
NZ (1) NZ510560A (enExample)
PL (1) PL195264B1 (enExample)
PT (1) PT1119370E (enExample)
SG (1) SG121778A1 (enExample)
SK (1) SK4662001A3 (enExample)
TR (1) TR200100974T2 (enExample)
WO (1) WO2000021558A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US7118742B2 (en) 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US6998108B1 (en) 1997-07-07 2006-02-14 La Jolla Institute For Allergy And Immunology Antibodies to p30 polypeptides and methods making and using same
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
HUP0103773A3 (en) * 1998-10-09 2003-10-28 Biogen Idec Ma Inc Cambridge Reversal of viral-induced systemic schock and respiratory distress by blockade of the lymphotoxin beta pathway
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
WO2001079496A2 (en) * 2000-03-13 2001-10-25 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
DK1674575T3 (da) * 2000-04-12 2010-11-29 Jolla Inst Allergy Immunolog Ligand for Herpes simplex-indgangsmediator og fremgangsmåder til anvendelse
WO2005000898A2 (en) * 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
EP1756162A1 (en) * 2004-03-23 2007-02-28 Biogen Idec MA Inc. Receptor coupling agents and therapeutic uses thereof
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
WO2008049053A2 (en) 2006-10-20 2008-04-24 Biogen Idec Ma Inc. Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
EP2207597B1 (en) * 2007-09-18 2020-02-19 La Jolla Institute for Allergy and Immunology Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment
CN106591446A (zh) * 2016-12-07 2017-04-26 中国人民解放军军事医学科学院微生物流行病研究所 细胞通路调控分子在作为药物靶点及诊断ebov感染中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
EP0536299B1 (en) 1990-06-27 2001-06-06 Biogen, Inc. Surface complexed lymphotoxin
AU692146B2 (en) 1990-06-27 1998-06-04 Biogen Idec Ma Inc. Lymphotoxin-beta, lymphotoxin-beta complexes, pharmaceutical preparations and therapeutic uses thereof
US7030080B2 (en) 1990-06-27 2006-04-18 Biogen, Inc. Lymphotoxin-β, lymphotoxin-β complexes, pharmaceutical preparations and therapeutic uses thereof
US5795964A (en) 1990-06-27 1998-08-18 Biogen, Inc. Lymphotoxin-beta and lymphotoxin-beta complexes
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
KR100475492B1 (ko) 1995-01-26 2005-03-14 바이오겐 아이덱 엠에이 인코포레이티드 항종양제로서의 림프독소-α/β 복합체 및항-림프독소-β수용체 항체
US6312691B1 (en) 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6291207B1 (en) * 1995-07-28 2001-09-18 Northwestern University Herpes virus entry receptor protein
IL129527A (en) * 1996-10-25 2006-12-10 Biogen Idec Inc Pharmaceutical preparations containing soluble lymphoxine-beta receptors
US7255854B1 (en) 1996-10-25 2007-08-14 Biogen, Inc. Use of lymphotoxin-β receptor blocking agents for the treatment of antibody mediated immunological diseases
GB9622660D0 (en) * 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US7060667B1 (en) 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
HUP0103773A3 (en) * 1998-10-09 2003-10-28 Biogen Idec Ma Inc Cambridge Reversal of viral-induced systemic schock and respiratory distress by blockade of the lymphotoxin beta pathway
TR200504220T2 (tr) 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
CN1678625A (zh) * 2002-07-01 2005-10-05 比奥根艾迪克Ma公司 人源化抗淋巴毒素β受体的抗体

Also Published As

Publication number Publication date
DE69931944D1 (de) 2006-07-27
EP1119370A1 (en) 2001-08-01
DK1119370T3 (da) 2006-10-02
IL142284A (en) 2009-11-18
US20040198635A1 (en) 2004-10-07
NZ510560A (en) 2003-09-26
ES2267294T3 (es) 2007-03-01
IS5882A (is) 2001-03-09
JP4713738B2 (ja) 2011-06-29
CA2344049A1 (en) 2000-04-20
HUP0103773A2 (hu) 2002-01-28
PL195264B1 (pl) 2007-08-31
CA2344049C (en) 2009-12-15
DE69931944T2 (de) 2007-02-08
IS2514B (is) 2009-06-15
US20020001585A1 (en) 2002-01-03
PL347177A1 (en) 2002-03-25
CN1200733C (zh) 2005-05-11
AU777492C (en) 2005-05-26
KR100888832B1 (ko) 2009-03-17
US20090087403A1 (en) 2009-04-02
CY1105059T1 (el) 2010-03-03
IL142284A0 (en) 2002-03-10
SG121778A1 (en) 2006-05-26
NO20011757L (no) 2001-06-08
AU777492B2 (en) 2004-10-21
BR9915025A (pt) 2001-08-14
US7452530B2 (en) 2008-11-18
NO20011757D0 (no) 2001-04-06
PT1119370E (pt) 2006-09-29
AU6296499A (en) 2000-05-01
WO2000021558A1 (en) 2000-04-20
EE200100211A (et) 2002-08-15
ATE329618T1 (de) 2006-07-15
CN1323223A (zh) 2001-11-21
EA006703B1 (ru) 2006-02-24
JP2010155852A (ja) 2010-07-15
KR20010080073A (ko) 2001-08-22
EA200100430A1 (ru) 2001-10-22
EE04661B1 (et) 2006-08-15
WO2000021558A9 (en) 2001-05-25
SK4662001A3 (en) 2001-11-06
JP2002527403A (ja) 2002-08-27
NO326905B1 (no) 2009-03-16
EP1119370B1 (en) 2006-06-14
CZ20011272A3 (cs) 2001-09-12
TR200100974T2 (tr) 2001-11-21

Similar Documents

Publication Publication Date Title
HUP0103773A3 (en) Reversal of viral-induced systemic schock and respiratory distress by blockade of the lymphotoxin beta pathway
HUP0103217A2 (hu) Orális folyékony mukoadhezív készítmények és alkalmazásuk
IL141403A0 (en) Deleted adenoviruses and methods of making and administering the same
SG83716A1 (en) Catalyst and use thereof in the production of vinyl acetate
EP1066039A4 (en) SUBSTITUTED QUINAZOLINE AND THEIR ANALOGS AND USES
SG85639A1 (en) Naphtalene derivative and liquid crystal composition comprising the same
PL345730A1 (en) Phenoxyacetic acid derivatives and medicinal compositions containing the same
TW437845U (en) Sheet-glass attaching construction and glass window using the attaching construction
SG63774A1 (en) Improvements in or relating to the monitoring of people
HRPK980256B1 (en) Intersection providing unhindered traffic flow and equal priority to all the traffic participants
HUP0102109A3 (en) Sweetener composition and uses thereof
GB9823245D0 (en) Pectins and the preparation thereof
GB9625279D0 (en) Manufacture of window frames and the like
SI1119370T1 (sl) Preobrat virusno induciranega sistemskega soka inrespiratornega distresa z blokado poti limfotoksina-beta
IL133104A0 (en) New - beta-amino and beta-azidocarboxylic acid derivatives the production thereof and the use thereof as endothelin receptor antagonists
AU3283299A (en) Probiotic composition and the use thereof
SG82014A1 (en) The use of aryl-cyclohexylamine derivatives against cns disorders
GB9805607D0 (en) Bite alarm
GB2266327B (en) Improvements in the installation of glazed frames in buildings
GB0127080D0 (en) Flow monitoring and control in multi-lateral wellbores
TW372588U (en) Improved structure of the blinds
GB2348602B (en) Sustantially improved thermal insulating netscreen adaptations for windows and the like
TW361329U (en) New design of ratchet wrench with double face and twin size
GB9803809D0 (en) The strimmer and rotovar adaptor
TW407689U (en) Connecting and installing structure for the outer frames of two extrusion windows

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees